PVPia K. Verkasalo

Pia K. Verkasalo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pia K. Verkasalo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sleep Duration and Breast Cancer: A Prospective Cohort Study

    by Pia K. Verkasalo, Kirsi Lillberg, Richard G. Stevens, Christer Hublin, Markku Partinen, Markku Koskenvuo, Jaakko Kaprio

    Breast cancer incidence has increased during recent decades for reasons that are only partly understood. Prevalence of sleeping difficulties and sleepiness has increased, whereas sleeping duration per night has decreased. We hypothesized that there is an inverse association between sleep duration and breast cancer risk, possibly due to greater overall melatonin production in longer sleepers. This population-based study includes information from women born in Finland before 1958. Sleep duration, other sleep variables, and breast cancer risk factors were assessed by self-administered questionnaires given in 1975 and in 1981. Breast cancer incidence data for 1976 to 1996 was obtained from the Finnish Cancer Registry. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained from Cox proportional hazards models adjusting for potential confounders. Altogether, 242 cases of breast cancer occurred over the study period among the 12,222 women with sleep duration data in 1975. For these women, the HRs for breast cancer in the short (≤6 hours), average (7-8 hours), and long sleep (≥9 hours) duration groups were 0.85 (CI, 0.54-1.34), 1.0 (referent), and 0.69 (CI, 0.45-1.06), respectively. Analysis restricted to the 7,396 women (146 cases) whose sleep duration in 1975 and 1981 were in the same duration group (stable sleepers) yielded HRs of 1.10 (CI, 0.59-2.05), 1.0, and 0.28 (CI, 0.09-0.88), with a decreasing trend (P = 0.03). This study provides some support for a decreased risk of breast cancer in long sleepers.


  • Open Access

    No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women

    by Ruth C. Travis, Michael Churchman, Sarah A. Edwards, Gillian Smith, Pia K. Verkasalo, C. Roland Wolf, Helga Wolf, Timothy J. Key

    The production of endogenous estradiol, and thus the risk of breast cancer, may be affected by functional polymorphisms in the genes coding for enzymes in the steroid biosynthesis pathway. Potentially important polymorphisms have been identified in three genes: CYP17, which encodes for a P450 enzyme that catalyzes 17α-hydroxylase and C17-20 lyase activities in the biosynthesis of androgens; CYP19, which encodes for aromatase, the enzyme involved in the conversion of androgens to estrogens; and HSD17-B1, which encodes for the 17β-hydroxysteroid oxidoreductase type 1 enzyme that reduces estrone to estradiol. Several studies have observedan association between risk for breast cancer and these polymorphisms (1). However, other studies have not found such an association, and the biological relationship of these polymorphisms with circulating estrogens has yet to be established. We assessed whether polymorphisms in CYP17, CYP19, or HSD17-B1 are associated with circulating levels of estradiol, the most biologically potent estrogen. Specifically, we examined a T to C substitution 34 bp upstream of the translation initiation site in the 5′ untranslated region of CYP17 among 634 premenopausal and 455 postmenopausal British women. Among the postmenopausal women, we also examined a [TTTA]n repeat allele beginning at bp 682 (intron 4) of CYP19, an associated TCT insertion/deletion polymorphism, a C to T substitution in the untranslated region of exon 10 of CYP19, and an A to G substitution in exon 6 of HSD17-B1 1,954 bp downstream of the first nucleotide in the translation initiation codon.Study participants included 636 premenopausal and 456 postmenopausal British women recruited to the Oxford arm of the European Prospective Investigation into Cancer and Nutrition and previously studied in a cross-sectional analysis of sex hormones and risk factors for breast cancer (2, 3). Details of the estradiol assays are described elsewhere (2). One postmenopausal and two premenopausal women were excluded from the current study due to insufficient buffy coat being available for molecular analyses.Genotyping on DNA extracted from buffy coat samples was conducted blind after the hormone assays had been completed. Eight hundred and ninety-eight samples were genotyped at the Cancer Research UK Genotyping Facility in Oxford. Blinded quality control samples (3.4%) were inserted to validate genotype identification procedures: concordance for the blinded samples was 100% for the CYP17 assay, 93.3% for the CYP19 intron 4 assay, 100% for the CYP19 exon 10 assay, and 100% for the HSD17-B1 assay. One hundred and ninety-eight samples were genotyped for the CYP17 single nucleotide polymorphism at the Biomedical Research Centre in Dundee as part of a previous unpublished study using similar methods. Genotype frequencies from the two laboratories were statistically similar: CYP17 TT, TC, and CC genotype frequencies were 40.0%, 45.9%, and 14.1%, respectively, for samples assayed in Oxford and 38.4%, 47.0%, and 14.7%, respectively, for samples assayed in Dundee (χ2 = 0.18, P = 0.9). Seven samples were genotyped for CYP17 at both laboratories and there was 100% concordance between the two sets of results.Estradiol values were logarithmically transformed to reduce the positive skewness of the distributions, and geometric mean hormone values and the corresponding95% confidence intervals are presented. ANOVA was used to evaluate the association between genotypes andestradiol concentrations. Estradiol concentrations in postmenopausal women, classified by their number of putative high-risk alleles, including single nucleotide polymorphisms in CYP17, CYP19 exon 10, and HSD17-B1 were also examined. Statistical analyses were repeated with adjustment for potential confounders including age (5-year age groups), body mass index [calculated as weight/height2 (kg/m2) and grouped <20, 20<22.5, 22.5<25, 25<27.5, ≥27.5], vigorous exercise (0, 1-2, 3-4, ≥5 hours per week), and number of days the blood sample was in the post (0-1, 2, ≥3 days; among postmenopausal women only). In the analyses of data from premenopausal women, adjustment was also made for stage of menstrual cycle (early follicular, late follicular, mid-cycle, early luteal, and late luteal defined as ≥22, 16-21, 12-15, 3-11, and 0-2 days before next menstrual period), smoking status (never, former, current), alcohol consumption (<0.50, 0.50<8.0, 8.080% power at a 0.05 significance level to detect differences of 25% in plasma concentrations between women with different genotypes. The results suggest that there is no large effect of the polymorphisms studied in CYP17, CYP19, and HSD17-B1 on endogenous estradiol concentrations; however, more data would be needed to establish whether or not there is a small effect.


  • Open Access

    Cancer Risk Near a Polluted River in Finland

    by Pia K. Verkasalo, Esa Kokki, Eero Pukkala, Terttu Vartiainen, Hannu Kiviranta, Antti Penttinen, Juha Pekkanen

    The River Kymijoki in southern Finland is heavily polluted with polychlorinated dibenzo-p-dioxins and dibenzofurans and may pose a health threat to local residents, especially farmers. In this study we investigated cancer risk in people living near the river (< 20.0 km) in 1980. We used a geographic information system, which stores registry data, in 500 m × 500 m grid squares, from the Population Register Centre, Statistics Finland, and Finnish Cancer Registry. From 1981 to 2000, cancer incidence in all people (N = 188,884) and in farmers (n = 11,132) residing in the study area was at the level expected based on national rates. Relative risks for total cancer and 27 cancer subtypes were calculated by distance of individuals to the river in 1980 (reference: 5.0–19.9 km, 1.0–4.9 km, < 1.0 km), adjusting for sex, age, time period, socioeconomic status, and distance of individuals to the sea. The respective relative risks for total cancer were 1.00, 1.09 [95% confidence interval (CI), 1.04–1.13], and 1.04 (95% CI, 0.99–1.09) among all residents, and 1.00, 0.99 (95% CI, 0.85–1.15), and 1.13 (95% CI, 0.97–1.32) among farmers. A statistically significant increase was observed for basal cell carcinoma of the skin (not included in total cancers) in all residents < 5.0 km. Several other common cancers, including cancers of the breast, uterine cervix, gallbladder, and nervous system, showed slightly elevated risk estimates at < 5.0 km from the river. Despite the limitations of exposure assessment, we cannot exclude the possibility that residence near the river may have contributed to a small increase in cancer risk, especially among farmers.


  • Soy Milk Intake and Plasma Sex Hormones: A Cross-Sectional Study in Pre- and Postmenopausal Women (EPIC-Oxford)

    by Pia K. Verkasalo, Paul N. Appleby, Gwyneth K. Davey, Timothy J. Key

    Soy beans contain high levels of the isoflavones genistein and daidzein and their glucosides. We investigated the relationship between soy milk intake and plasma concentrations of estradiol, sex hormone-binding globulin, and, in premenopausal women, follicle-stimulating hormone, luteinizing hormone, and progesterone in a cross-sectional study of 636 premenopausal and 456 postmenopausal British women. Sixty-five percent of the women were vegetarians or vegans. Data on soy milk intake and other factors were obtained from a validated food frequency questionnaire, hormone concentrations were measured by immunoassays, and variations in geometric means were compared using analysis of covariance. We observed no statistically significant trends or meaningful associations between soy milk intake and circulating sex hormones. Adjusting for factors possibly affecting circulating hormone concentrations did not materially alter the results. We conclude that soy milk intake does not change plasma concentrations of sex ...


  • Open Access

    Subsequent primary cancers after basal‐cell carcinoma: A nationwide study in Finland from 1953 to 1995

    by Tiina Milán, Eero Pukkala, Pia K. Verkasalo, Jaakko Kaprio, Christer T. Jansén, Markku Koskenvuo, Lyly Teppo